| Abstrakt: |
Introduction: Type 1 diabetes is an autoimmune disease. it occurs when the immune system attacks the pancreatic islets. As a result of inflammation and oxidative stress, beta cells are destroyed and eventually the source of insulinproducing cells is lost and leads to hyperglycemia. The treatment of this disease has faced challenges and limitations up to now. Astaxanthin is a carotenoid with antioxidant properties, which significantly increases cell survival by reducing inflammation and oxidative stress. Gamma-aminobutyric acid (GABA) is a neurotransmitter that modulates the activity of alpha and beta cells in pancreatic islets. Methods and Materials: In this study, 30 male Wistar rats (approximately 200 gr) were used. After intraperitoneal injection of STZ (55 mg/kg) and induction of diabetes, rats were randomly divided into five groups (n=6): control, diabetic, astaxanthin (20 mg/kg), GABA (100 mg/kg) and synergic (GABA+AST). Finally, blood sugar level, C peptide level and serum insulin were evaluated and the pancreas of rats was removed to check the tissue parameters and perform Real Time PCR test. Results: The blood sugar level of rats treated with GABA, astaxanthin and synergic decreased significantly compared to diabetic rats. In addition, the amount of c-peptide and insulin in the serum of the mentioned groups increased compared to the control group. The results of the immunohistochemical analysis showed significant expression of insulin in the GABA, astaxanthin and synergic groups compared to the diabetic group. The expression of PDX1 and NEUROG3 genes also increased significantly in the GABA, astaxanthin and synergic groups compared to the control group. Conclusion: The obtained results show that consumption of astaxanthin and GABA compounds increases insulin production and reduces blood sugar levels in the diabetic patients. [ABSTRACT FROM AUTHOR] |
